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Abstract
Introduction: Achalasia is a primary motor disorder of the oesophagus characterised by absence of peristalsis and insuf-
ficient lower oesophageal sphincter relaxation. With new advances and developments in achalasia management, there is an
increasing demand for comprehensive evidence-based guidelines to assist clinicians in achalasia patient care.
Methods: Guidelines were established by a working group of representatives from United European Gastroenterology,
European Society of Neurogastroenterology and Motility, European Society of Gastrointestinal and Abdominal Radiology,
and the European Association of Endoscopic Surgery in accordance with the Appraisal of Guidelines for Research and
Evaluation (AGREE) II instrument. A systematic review of the literature was performed and the certainty of the evidence was
assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology.
Recommendations were voted upon using a nominal group technique.
Results: These guidelines focus on the definition of achalasia, treatment aims, diagnostic tests, medical, endoscopic and
surgical therapy, management of treatment failure, follow-up and oesophageal cancer risk.
Conclusion: These multidisciplinary guidelines provide a comprehensive evidence-based framework with recommendations
on the diagnosis, treatment and follow-up of adult achalasia patients.
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Achalasia is a primary motility disorder in which insuf-
ficient relaxation of the lower oesophageal sphincter
(LOS) and absent peristalsis result in stasis of ingested
foods and subsequently, lead to oesophageal symptoms
of dysphagia, regurgitation, chest pain or weight loss.1
Achalasia occurs as an effect of destruction of enteric
neurons controlling the LOS and oesophageal body
musculature by an unknown cause, most likely inflam-
matory. Idiopathic achalasia is a rare disease and
affects individuals of both sexes and all ages. The
annual incidence is estimated between 1.07–2.2 cases
per 100,000 individuals with prevalence rates estimated
between 10–15.7 per 100,000 individuals.2–4
A diagnosis of achalasia should be considered when
patients present with dysphagia in combination with
other oesophageal symptoms and when upper endos-
copy ruled out other disorders. Barium esophagogram
may reveal a classic ‘‘bird’s beak’’ sign, oesophageal
dilation, or a corkscrew appearance. Oesophageal
manometry is the golden standard for the diagnosis
of achalasia; incomplete relaxation of the LOS,
reflected by an increased integrative relaxation pres-
sure, in absence of normal peristalsis, are the diagnostic
hallmarks. The use of high-resolution manometry
(HRM) has led to the subclassification of achalasia
into three clinically relevant groups based on oesopha-
geal contractility patterns, as seen in Table 1.
The clinical care of patients with achalasia has chan-
ged significantly in the past decade under influence of
new developments such as high-resolution manometry,
per-oral endoscopic myotomy and studies providing
new insights regarding achalasia subtypes, cancer risk
and follow-up. Given the substantial growth of know-
ledge in the past years, there is need for a comprehen-
sive, evidence-based European guideline covering all
aspects of the disease. This multidisciplinary guideline
aims to provide an evidence-based framework with rec-
ommendations on the diagnosis, treatment and follow-
up of adult achalasia patients. Chagas disease and
achalasia secondary to other disorders, as can be seen
after fundoplication, bariatric surgery, sarcoid infiltra-
tion, opiate usage or malignancy, is not covered by this
guideline. This guideline is intended for clinicians
involved in their management, including gastroenter-
ologists, endoscopists, radiologists, gastrointestinal sur-
geons, dietitians and primary care practitioners.
Methodology
The achalasia guideline working group
Ten researchers and clinicians with recognised expertise
in the field of clinical achalasia management were gath-
ered (AB, GB, PF, AP, SR, AS, AT, ET, BW, GZ) on
behalf of United European Gastroenterology (UEG),
European Society of Neurogastroenterology and Motility
(ESNM), the European Society of Gastrointestinal and
Abdominal Radiology (ESGAR), and The European
Association of Endoscopic Surgery (EAES) to form a
guideline expert working group. All concerned societies
were contacted and asked to support the guideline by
appointing one or two representatives for the guideline
committee. First, the guideline development team (RON,
AB, and ML) drafted the guideline protocol and the pre-
liminary list of clinical topics to be covered by the guide-
lines. This list was circulated to a panel of achalasia
patients. Based upon patients’ interests, the final list of
research questions was formatted into the PICO (patient,
intervention, control, outcome) framework, and presented
to all members of the guideline working group at an initial
meeting which occurred on 23rd of October at UEG week
2018. All working group members were assigned to one of
the subgroups (diagnosis, treatment or follow-up) and
were responsible for the elaboration of one or multiple
research questions. Results of the search strategies and
GRADE assessments were first discussed in conference
calls by each group and checked again for completeness,
after which these documents were updated and subse-
quently sent to the entire group in advance of a face-to-
face consensus meeting.
From assessment of evidence to recommendation
An electronic literature search was performed on the
18th of October 2018 using MEDLINE, EMBASE
(accessed via Ovid), The Cochrane Database of
Systematic Reviews (The Cochrane Library), and the
Cochrane Central Register of Controlled Trials
(CENTRAL) without restrictions of language or pub-
lication year. The search strategy and the process of
study selection categorised per research question can
be found in appendix A. Risk of bias was assessed
using the appropriate study-design specific tools
(appendix B). The certainty of evidence was assessed
using the GRADE methodology (www.gradewor-
kinggroup.org) and for each outcome graded into
four levels: high, moderate, low, or very low quality
(Table 2). Based on the certainty of evidence and the
balance between desirable and undesirable outcomes,
patient values and preferences, applicability, feasibility,
equity and costs/resources, recommendations were
categorised into four final categories (strong or condi-
tional recommendations in favour of or against an
intervention), as proposed by GRADE (Table 3).
In case of insufficient or limited evidence, research
questions were answered by and classified as ‘expert
opinion’. The results of data extraction, the risk of
bias and quality of the evidence assessments are pre-
sented in appendix C and appendix D.
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Table 1. Manometric subtypes of achalasia.
Type I Classic achalasia  Median IRP> Cutoff*
 100% failed peristalsis
Type II Achalasia with
oesophageal compression
 Median IRP> Cutoff*
 100% failed peristalsis
 20% pan-oesophageal pressurization
Type III Spastic achalasia  Median IRP> Cutoff*
 No normal peristalsis
 20% premature contractions with DCI>450
DCI, Distal Contractile Integral; IRP, Integrated Relaxation Pressure. *note: the cutoff for IRP is catheter-depending, varying between 15 and 28 mmHg.
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Consensus process
In order to establish consensus-based recommenda-
tions, a second physical meeting was organised in
Amsterdam, the Netherlands on the 11th of April
2019. GRADE assessments and recommendations
were presented and discussed. Voting was conducted
according to the nominal group technique and based
upon a six-point Likert scale (1: strongly disagree; 2:
mostly disagree; 3: somewhat disagree; 4: somewhat
agree; 5: mostly agree; 6: strongly agree). A recommen-
dation was approved if > 75% of the members agreed
(reflected by a Likert score of 4–6).
Recommendations
Clinical questions formed the basis of the systematic
literature reviews (appendix A in supplementary
material). The working group formulated 30 recom-
mendations based on these reviews (Table 4).
1. Achalasia diagnosis
1.1 What is the current definition of achalasia?
Recommendation 1.1
Achalasia is a disorder characterised by insufficient LOS relaxation
and absent peristalsis. It is usually primary (idiopathic) but can be
secondary to other conditions that affect oesophageal function. In
idiopathic achalasia the enteric neurons controlling the LOS and
oesophageal body musculature are affected by an unknown cause,
most likely inflammatory.
Expert opinion recommendation
Consensus: 100% agree [Vote: Aþþ, 100%; Aþ, 0%; A, 0%; D 0%;
Dþ, 0%; Dþþ, 0%]
1.2 What is the value of HRM and conventional
manometry in achalasia diagnosis?
The diagnosis of achalasia not only requires impaired
OGJ relaxation, but also absent or abnormal peristal-
sis. Therefore, oesophageal manometry is considered
as being the gold standard for the diagnosis of
achalasia, as it evaluates both pressures of the lower
oesophageal sphincter (LOS) and contractility of the
oesophageal body. Worldwide, high-resolution mano-
metry (HRM), usually defined as manometry carried
out with a catheter with at least 21 pressure sensors
spaced at 1-cm intervals,5 is rapidly replacing conven-
tional manometry. The generally perceived advantages
of HRM over conventional manometry are that pos-
itioning of the catheter is less critical and that interpret-
ation of the recorded pressures, displayed in the form of
topographical colour-coded plots, is more intuitive.





the guideline For the patient For the clinician
Strong ‘‘We recommend . . .’’ Most individuals in this situ-
ation would want the recom-
mended course and only a
small proportion would not.
Most individuals should receive the recommended
course of action. Formal decision aids are not likely
to be needed to help individuals make decisions con-
sistent with their values and preferences.
Conditional ‘‘We suggest . . .’’ The majority of individuals in
this situation would want the
suggested course, but many
would not.
Different choices would be appropriate for different
patients. Decision aids may be useful in helping indi-
viduals in making decisions consistent with their
values and preferences. Clinicians should expect to
spend more time with patients when working towards
a decision.
Table 2. Grading of Recommendations Assessment, Development,




High We are very confident that the true effect lies close
to the estimate of the effect.
Moderate We are moderately confident in the effect estimate.
The true effect is likely to be close to the estimate
of effect, but there is a possibility that it is sub-
stantially different.
Low Our confidence in the estimate is limited. The true
effect may be substantially different from the esti-
mate of effect.
Very low We have very little confidence in the effect esti-
mate. The true effect is likely to be substantially
different from the estimate of effect.
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Table 4. Summary of recommendations of the United European Gastroenterology Clinical Guidelines Committee for the diagnosis,





1.1 Achalasia is a disorder characterised by insufficient LOS relaxation and
absent peristalsis. It is usually primary (idiopathic) but can be secondary
to other conditions that affect oesophageal function. In idiopathic achalasia
the enteric neurons controlling the LOS and oesophageal body musculature
are affected by an unknown cause, most likely inflammatory.
Expert opinion – 100%
1.2 We recommend using high-resolution manometry (with topographical
pressure presentation) to diagnose achalasia in adult patients with sus-
pected achalasia.
Strong Moderate 100%
1.3 We suggest using a barium esophagram to diagnose achalasia if mano-
metry is unavailable, although it is less sensitive than oesophageal mano-
metry. The working group suggests using timed barium esophagram, if
available, over standard barium esophagram.
Conditional Moderate 100%
1.4 We suggest against making the diagnosis of achalasia solely based on
impaired OGJ distensibility as measured with impedance planimetry.
Expert opinion – 100%
1.5 I. We suggest against making the diagnosis of achalasia solely based on
endoscopy.
Expert opinion – 100%
II. We suggest performing endoscopy in all patients with symptoms sug-
gestive of achalasia to exclude other diseases.
Expert opinion – 77.8%
1.6 We suggest additional testing using CT or endoscopic ultrasound only
in those achalasia patients suspected of malignant pseudo-achalasia.
Multiple recognised risk factors for malignant pseudo-achalasia
e.g. age> 55 yrs, duration of symptoms< 12 months, weight loss >10 kg,
severe difficulty passing LES with scope may prompt
further imaging.
Conditional Low 100%
1.7 We suggest to provide the patient with the following information on the
disease and the treatment:
Information on the disease
 normal function of oesophagus
 rare condition that affects the neurons, leads to LES dysrelaxation and
absent peristalsis, exact cause not known
 no increased chance of disease in siblings
 what might happen if left untreated
 no progression to other organs
 small increased risk of cancer
Information on treatment options
 explanation of all treatment options, choice of treatment is based upon
shared-decision making.
 treatment is not curative, but does improve symptoms
 risk of complications
 risk of reflux
 efficacy of treatments
Expert opinion – 100%
Treatment
2.1 I. We suggest that in the treatment of achalasia symptom relief should be
regarded as the primary treatment aim.
Expert opinion – 100%
II. We suggest that improvement of objectively measured oesophageal
emptying on barium esophagram should be regarded as an important
additional treatment aim.
Expert opinion – 100%
2.2 We suggest against the use of calcium blockers, phosphodiesterase inhibi-
tors or nitrates for the treatment of achalasia.
Expert opinion – 100%
(continued)





2.3 Botulinum toxin therapy can be considered an effective and safe
therapy for short-term symptom relief in oesophageal
achalasia.
Conditional Moderate 88.9%
2.4 Graded pneumatic dilatation is an effective and relatively safe treatment
for oesophageal achalasia.
Strong High 100%
2.5 POEM is an effective and relatively safe treatment for Achalasia. Strong High 100%
2.6 Laparoscopic Heller myotomy combined with an anti-reflux procedure is an
effective and relatively safe therapy for achalasia.
Strong High 100%
2.7 We suggest taking age and manometric subtype into account when select-
ing a therapeutic strategy.
Conditional Moderate 100%
2.8 I. Treatment decisions in achalasia should be made based on patient-
specific characteristics, patient preference, possible side effects and/or
complications and a center’s expertise. Overall, graded repetitive PD,
LHM and POEM have comparable efficacy.
Strong Moderate 100%
II. Botulinum toxin should be reserved for patients that are unfit for more
invasive treatments, or in whom a more definite treatment needs to be
deferred.
Conditional Moderate 100%
2.9 We suggest treating recurrent or persistent dysphagia after laparoscopic
Heller myotomy with PD, POEM or redo surgery.
Conditional Very low 100%
2.10 We suggest treating recurrent or persistent dysphagia after POEM with
either re-POEM, laparoscopic Heller myotomy or pneumatic dilation.
Conditional Very low 100%
2.11 Oesophagectomy should be considered the last resort to treat achalasia,
after all other treatments have been considered.
Expert opinion – 100%
2.12 We suggest against oesophageal stents and intrasphincteric injection of
sclerosing agents in the treatment of achalasia.
Expert opinion – 100%
Follow-up
3.1 I. Patients with recurrent or persistent dysphagia after initial treatment
should undergo repeat evaluation with timed barium esophagram with or
without oesophageal manometry.
Expert opinion – 100%
II. Repeat endoscopy should be considered in patients with recurrent
dysphagia.
Expert opinion – 100%
3.2 I. In patients with persistent or recurrent chest pain, inappropriate emp-
tying due to ineffective initial treatment or recurrent disease should be
excluded by TBE with or without oesophageal manometry. For type III
achalasia, we suggest a repeat HRM to exclude or confirm persistent spas-
tic contractions.
Expert opinion – 100%
II. If there is no evidence of impaired oesophageal emptying, empirical
treatment with PPI, endoscopy and/or 24 hr pH-(impedance)metry can be
considered.
Expert opinion – 100%
3.3 I. We suggest follow-up endoscopy to screen for GERD in patients treated
with myotomy without anti-reflux procedure.
Expert opinion – 100%
II. In case of reflux symptoms in absence of reflux esophagitis, TBE,
empiric PPI therapy, and/or 24-h oesophageal pH-(impedance)monitoring
can be considered.
Expert opinion – 100%
III. Proton pump inhibitors are the first line treatment of GORD after
achalasia treatment. We recommend lifelong PPI therapy in patients
with oesophagitis> grade A (LA classification).
Expert opinion – 100%
3.4 We suggest against performing systematic screening for dysplasia and car-
cinoma. However, the threshold of upper GI endoscopy
should be low in patients with recurrent symptoms and
longstanding achalasia.
Conditional Low 100%
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In 4 of the 5 included studies, the diagnosis of acha-
lasia was made more often with HRM than with con-
ventional manometry.6–9 However, one may argue that
a higher rate of achalasia diagnosis with HRM does not
prove that HRM is better than conventional manome-
try; HRM might also lead to more false-positive find-
ings. The only prospective randomised trial that
compared HRM and conventional manometry9 had
the additional advantage of defining the clinical out-
come after 6 months as the gold standard, and found
a superior sensitivity of HRM for the diagnosis of acha-
lasia to that of conventional manometry (93 vs 78%).
The specificities of both tests were equal (100%).9
In two studies the diagnostic values of imaging tech-
niques were compared with manometry.10,11 The results
of these two studies lend some support to the notion
that manometry rather than imaging is the gold stand-
ard for the diagnosis of achalasia.
Recommendation 1.2
We recommend using high-resolution manometry (with topo-
graphical pressure presentation) to diagnose achalasia in adult
patients with suspected achalasia.
Strong recommendation, moderate certainty of evidence
Consensus: 100% agree [Vote: Aþþ, 66.7%; Aþ, 33.3%; A, 0%; D
0%; Dþ, 0%; Dþþ, 0%]
1.3 What is the value of (timed) barium swallow
studies in achalasia diagnosis?
The barium esophagram is generally seen as a valuable
and complementary, but relatively insensitive, diagnos-
tic test. One study evaluated the diagnostic value of
barium esophagraphy in comparison with HRM and
found a high sensitivity, but poor specificity for detect-
ing dysmotility. The authors conclude that barium swal-
low studies accurately rule out achalasia-related
dysmotility but are not very helpful in diagnosing
other causes of dysmotility.12 Two studies comparing
barium esophagraphy with conventional manometry
found sensitivities for achalasia diagnosis between 58 –
75%.11,13 However, as the positive predictive accuracy
was 96%, the authors concluded that the barium eso-
phagram is a useful tool in achalasia diagnosis.11 Similar
sensitivity and specificity rates were obtained in another
study comparing barium swallow studies with HRM;
the diagnostic sensitivity, specificity and accuracy of
the barium esophagram were 78.3%, 88.0%, and
83.0%, respectively.14 Consequently, it may be con-
cluded that diagnosing achalasia by using barium eso-
phagram alone has a limited yield. The technique of
timed barium esophagram (TBE) is similar to the
usual barium swallow study but uses set time intervals
(1, 2 and 5minutes) after ingestion of a fixed barium
suspension, to measure height and width of the barium
column in order to assess oesophageal emptying more
objectively (Figure 1).15 Because of this advantage, TBE
is generally preferred over a standard barium esopha-
gram. One study compared TBE with HRM, and
found a sensitivity of 85% and specificity of 86%.15
Recommendation 1.3
We suggest using a barium esophagram to diagnose achalasia if
manometry is unavailable, although it is less sensitive than
oesophageal manometry. The working group suggests using
timed barium esophagram, if available, over standard barium
esophagram.
conditional recommendation, moderate certainty of evidence
Consensus: 100% agree [Vote: Aþþ, 88.9%; Aþ, 11.1%; A, 0%; D
0%; Dþ, 0%; Dþþ, 0%]
1.4 What is the value of impedance planimetry in
the diagnosis of achalasia?
Oesophageal impedance planimetry is a technique in
which the cross-sectional area of the oesophagus is sim-
ultaneously measured at multiple levels using a saline-
filled cylindrical bag containing an array of impedance
electrodes.6 The commercially-available device for endo-
luminal impedance planimetry is known as Endoflip.
Studies using impedance planimetry have consistently
demonstrated that the distensibility of the oesophago-
gastric junction (OGJ) is reduced in untreated achalasia
compared to healthy controls.16–19 A systematic review
identified 6 studies with data on oesophago-gastric junc-
tion (OGJ) distensibility in untreated achalasia patients
(n¼ 154) and 5 studies with data in healthy subjects
(n¼ 98) and found that at 40-mL distension there
was a clear difference between the two groups (point
estimates < 1.6mm2/mmHg and > 2.7mm2/mmHg in
patients and controls respectively).20
However, in order to distinguish achalasia from
OGJ outflow obstruction, information about the motil-
ity of the tubular oesophagus is required, which is not
provided by impedance planimetry measurement.
Recent studies indicate that dynamic impedance plan-
imetry can also provide information on peristalsis.21,22
However, this technique assesses distension-, rather
than swallow-induced contractions, and requires sed-
ation. Furthermore, high-quality diagnostic studies
comparing impedance planimetry with the gold stand-
ard HRM are not available yet. In line with this, one
recommendation from a recent AGA clinical practice
update on functional lumen imaging is that clinicians
should not make a diagnosis of achalasia based on
impedance planimetry alone.23
There is data to suggest that impedance planimetry
may be used as an additional tool to diagnose achalasia
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in patients who do not meet the manometric criteria
(Chicago 3.0) for achalasia. In 13 patients with symp-
toms and signs of achalasia, but with manometrically
normal integrated relaxation pressure (IRP), OGJ dis-
tensibility was below the lower limit of normal.
Treatment of these patients as if the diagnosis
were achalasia resulted in a decrease of symptoms.24
This observation suggests that impedance planimetry
may be a useful complimentary diagnostic tool for
the diagnosis of achalasia, in a subset of patients with
a low IRP.
Recommendation 1.4
We suggest against making the diagnosis of achalasia solely based
on impaired OGJ distensibility as measured with impedance
planimetry.
Expert opinion recommendation
Consensus: 100% agree [Vote: Aþþ, 100%; Aþ, 0%; A, 0%; D 0%;
Dþ, 0%; Dþþ, 0%]
1.5 What is the value of endoscopy in achalasia
diagnosis?
Thorough endoscopic evaluation of the gastro-oeso-
phageal junction and gastric cardia is recommended
in all patients with symptoms suggestive of achalasia
to exclude other diseases, especially to rule out malig-
nancies. However, the value of endoscopy in achalasia
diagnosis is relatively low. Depending on the stage of
disease, endoscopic evaluation can suggest a diagnosis
of achalasia in 30-50% of patients. Achalasia diagnosis
can easily be missed, as endoscopic abnormalities are
uncommon in early-stage achalasia.25–27 In more
advanced stages, a diagnosis of achalasia is supported
by endoscopic findings such as an oesophageal dilata-
tion with axis deviation and tortuosity and retained
saliva and food in the oesophagus.28–30
Recommendation 1.5
a. We suggest against making the diagnosis of achalasia solely
based on endoscopy.
Expert opinion recommendation
Consensus: 100% agree [Vote: Aþþ, 100%; Aþ, 0%; A, 0%; D 0%;
Dþ, 0%; Dþþ, 0%]
b. We suggest performing endoscopy in all patients with symptoms
suggestive of achalasia to exclude other diseases.
Expert opinion recommendation
Consensus: 77.8% agree [Vote: Aþþ, 77.8%; Aþ, 0%; A, 0%; D
0%; Dþ, 22.2%; Dþþ, 0%]
1.6 In which patients should additional
diagnostic tests be performed in order to
exclude pseudo-achalasia?
Malignant pseudo-achalasia is the condition in which a
patient is initially diagnosed with achalasia, and some-
times even treated for achalasia, but later found to have
an underlying malignancy as the primary cause. This
can occur in a submucosally growing adenocarcinoma
of the cardia, locally advanced pancreatic cancer, sub-
mucosal metastases or anti-Hu-producing carcinomas
(typically small cell lung carcinomas).31 Certainly not
all patients diagnosed with achalasia should undergo
additional testing in the form of a CT scan or endo-
scopic ultrasound to rule out malignancy, however,
Figure 1. Interpretation of timed barium esophagram. Radiographs taken 0, 1, 2 and 5 minutes in left posterior oblique position after
ingestion of 100 to 200 mL low-density barium suspension in an achalasia patient. Measurement of height and width of barium column,
measured from the OGJ to the barium-foam interface. Barium height of >5 cm at 1 min and >2 cm at 5 min are suggestive of achalasia.
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valuable time is missed if malignancy is not detected in
an early stage. Only two studies have addressed the
issue of how to identify patients with malignant
pseudo-achalasia.32,33 Both case-control studies identi-
fied the same differences between patients with primary
achalasia and patients with malignant pseudo-achala-
sia: relatively short duration of symptoms, considerable
weight loss and older age. The study by Ponds et al also
identified difficulty introducing the endoscope in the
stomach as mentioned by the endoscopist as a risk
factor. A model was produced in which presence of
less than 2 risk factors did not result in increased risk
for malignancy, while risk increased from presence of 2
risk factors or more. The authors recommend add-
itional testing in these patients.
Recommendation 1.6
We suggest additional testing using CT or endoscopic ultrasound
only in those achalasia patients suspected of malignant pseudo-
achalasia. Multiple recognised risk factors for malignant pseudo-
achalasia e.g. age> 55 yrs, duration of symptoms< 12 months,
weight loss> 10 kg, severe difficulty passing LES with scope may
prompt further imaging.
Conditional recommendation, low certainty of evidence
Consensus: 100% agree [Vote: Aþþ, 66.7%; A22.2%; A, 11.1%; D
0%; Dþ, 0%; Dþþ, 0%]
1.7 What information should the newly
diagnosed patient receive?
We recommend to provide the patient with information
on the disease and the treatment stated in Table 1.7.1.
2. Achalasia treatment
2.1 What should we aim for when treating
achalasia patients?
Treatment can be considered for the purpose of reducing
symptoms and consequently, improvement of quality of
life. As the evidence for the use of standardized question-
naires in the clinical setting is limited, a thorough clinical
assessment of oesophageal symptoms before and after
therapy should be used to evaluate treatment success.
Secondly, treatment might prevent progression to end-
stage disease and occurrence of late complications, such
as aspiration and carcinogenesis. However, data on the
natural history of disease to support this is scarce. There
are series showing that if patients remain untreated,
oesophageal distension progresses over a period of many
years.34,35 There is some indirect evidence that treatment
can prevent progression of the disease; in a study evaluat-
ing patients treatedwith pneumatic dilation (PD), the per-
sistence of oesophageal stasis on timed barium
esophagraphy was associated with progressive oesopha-
geal dilatation of 0.5 cm in a 2-year period, whereas suc-
cessful PD (no stasis on TBE) was not.36 Additionally,
several surgical studies showed that treatment directed
to LOS pressure is less effective in patients with late-
stage disease and decompensated oesophagus.37–39 In
summary, there is some indirect evidence that adequate
treatment might reduce the risk of progressive oesopha-
geal dilation in patients with achalasia, potentially pre-
venting a state of gross oesophageal dilation, which in
turn isassociatedwithpooroutcome. Inaddition toameli-
oration of symptoms, improvement of objectively mea-
sured oesophageal emptying should therefore be
regarded as an important additional treatment aim.
Recommendation 2.1
a. We suggest that in the treatment of achalasia symptom relief
should be regarded as the primary treatment aim.
Expert opinion recommendation
Consensus: 100% agree [Vote: Aþþ, 100%; Aþ, 0%; A, 0%; D 0%;
Dþ, 0%; Dþþ, 0%]
b. We suggest that improvement of objectively measured oesopha-
geal emptying on barium esophagram should be regarded as
an important additional treatment aim.
Expert opinion recommendation
Consensus: 100% agree [Vote: Aþþ, 66.7%; A22.2%; A, 11.1%; D
0%; Dþ, 0%; Dþþ, 0%]
2.2 What is the role of oral pharmacological
therapy in achalasia?
There is no convincing evidence that treatment with
smooth muscle relaxants (calcium blockers, phospho-
diesterase inhibitors or nitrates) provides symptomatic
Table 1.7.1. Information the newly diagnosed achalasia patient
should receive.
Information on the disease
 normal function of oesophagus
 rare condition that affects the neurons, leads to LOS dysre-
laxation and absent peristalsis, exact cause not known
 no increased chance of disease in siblings
 what might happen if left untreated
 no progression to other organs
 small increased risk of cancer
Information on treatment options
 explanation of all treatment options, choice of treatment is
based upon shared-decision making.
 treatment is not curative, but does improve symptoms
 risk of complications
 risk of reflux
 efficacy of treatments
Expert opinion recommendation
Consensus: 100% agree [Vote: Aþþ, 100%; Aþ, 0%; A, 0%; D 0%;
Dþ, 0%; Dþþ, 0%]
Oude Nijhuis et al. 21
relief in adults with achalasia. The table presented in
appendix C summarises the available literature. None
of the studies is of sufficiently high quality, has suffi-
cient sample size and measured adequate endpoints to
answer this question.40–46 Treatment with smooth
muscle relaxants can cause side-effects, and is therefore
not recommended. It should certainly not delay an
effective endoscopic or surgical treatment. Whether
chest pain that is presumed to be due to spastic con-
tractions can be relieved with medical therapy will be
discussed in question 3.2.
Recommendation 2.2
We suggest against the use of calcium blockers, phosphodiesterase
inhibitors or nitrates for the treatment of achalasia.
Expert opinion recommendation
Consensus: 100% agree [Vote: Aþþ, 66.7%; Aþ, 33.3%; A, 0%; D
0%; Dþ, 0%; Dþþ, 0%]
2.3 What is the comparative therapeutic efficacy
and safety of endoscopic botulinum toxin
injection in the treatment of achalasia?
Endoscopic injection of botulinum toxin (BTX) in the
LOS has been compared with laparoscopic Heller
myotomy (LHM) or endoscopic pneumatic dilation
(PD) in several RCTs.47–49 The results of these studies
all point in the same direction; BTX injections result in
a reduction in LOS pressure, stasis and symptoms in
the short term, but generally the disease symptoms and
signs recur with time. PD and BTX treatment are
equally effective at the short term, while PD is the
more effective endoscopic treatment in the long term
(greater than six months). Heller and BTX treatment
are equally effective at the short term; Heller is the more
effective treatment in the long term (greater than six
months).
Recommendation 2.3
Botulinum toxin therapy can be considered an effective and safe
therapy for short-term symptom relief in oesophageal achalasia.
Conditional recommendation, moderate certainty of evidence
Consensus: 88.9% agree [Vote: Aþþ, 88.9%; Aþ, 0%; A, 0%; D,
11.1%; Dþ, 0%; Dþþ, 0%]
2.4 What is the comparative therapeutic efficacy
and safety of endoscopic dilation?
Pneumatic dilation (PD) has been compared to endo-
scopic botulinum toxin injections in the LOS, POEM
and Heller myotomy. A factor of importance when
comparing the different studies is the PD regimen fol-
lowed, which varies widely. Broadly speaking,
treatment regimens with multiple dilations performed
in case of recurrent symptoms, increase the efficacy. A
single series of PDs is less efficacious than LHM or
POEM, while there is no difference in safety between
the two treatment groups.50–53 In studies in which
repeated dilation was allowed upon symptom recur-
rence, the efficacy of PD generally approached that of
LHM at a similar safety profile.54–58 Given the risk of
perforation, it is always advised to start with a 30-mm
balloon in an untreated achalasia patient. A second
dilation with 35mm will prolong the time to
recurrence.54,59
Recommendation 2.4
Graded pneumatic dilatation is an effective and relatively safe
treatment for oesophageal achalasia.
Strong recommendation, high certainty of evidence
Consensus: 100% agree [Vote: Aþþ, 100%; Aþ, 0%; A, 0%; D 0%;
Dþ, 0%; Dþþ, 0%]
2.5 What is the comparative therapeutic efficacy
and safety of per-oral endoscopic myotomy?
POEM appears to be a safe treatment option with a low
rate of serious adverse events.50,60 Although no long-
term (beyond 2 years) follow-up data are available yet,
POEM appears to be equally effective to LHM. In a
recently published multicentre RCT, treatment success
rate, defined as a reduction in Eckardt score <3 and the
absence of severe complications or need for re-treat-
ment, after 2 years of follow-up was significantly
higher in patients treated with POEM compared to
patients treated with PD.50 In this study, patients
assigned to the PD arm were treated with a single
30-mm dilation, and received a second dilation with a
35-mm balloon if still symptomatic (which was the case
in 50 of 66 (76%) patients). GORD occurs more fre-
quently after POEM than after LMH or PD, but high
grades of oesophagitis are uncommon.61,62 However,
one should note that it is very challenging to objectify
GORD in achalasia patients, as gastro-oesophageal
acid reflux is hard to differentiate from fermentation
due to stasis. Nevertheless, in patients with a high
risk of post-procedure GORD who are unwilling to
use proton pump inhibitor (PPI) therapy, LHM or
PD might be preferred over POEM.
Recommendation 2.5
Per-oral endoscopic myotomy is an effective and relatively safe
treatment for oesophageal achalasia.
Strong recommendation, high certainty of evidence
Consensus: 100% agree [Vote: Aþþ, 100%; Aþ, 0%; A, 0%; D 0%;
Dþ, 0%; Dþþ, 0%]
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2.6 What is the comparative therapeutic efficacy
and safety of surgical myotomy?
During a surgical cardiomyotomy, the spastic LOS is
disrupted by cleaving the muscle layers of both the LOS
and cardia, allowing passage of foods. Nowadays, the
procedure is typically performed laparoscopically and
combined with a partial anti-reflux procedure (fundo-
plication). A complete 360-degree wrap should be
avoided in achalasia patients to prevent worsening,
rather than relieving, the dysphagia.63 Six RCTs com-
pared the efficacy of LHM versus PD (two of them
reporting long-term results) and multiple meta-analyses
were performed.51–58,64,65 These studies report a similar
outcome for LHM and PD when multiple sessions of
graded dilations were allowed (sequential dilations).
However, LHM performed better than two sessions
of PD. The meta-analysis (where PD outcome was
assessed independently of the number of PD sessions)
was in favour of LHM. LHM was more effective than
PD in type III achalasia in a sub-group analysis of the
European Achalasia Trial. One RCT compared LHM
to botulinum toxin injection and showed a better out-
come for LHM after 6 months of follow-up, after an
initial similar response.49 There is only one RCT, com-
paring LHM and POEM, showing a similar symptom-
atic outcome for the two treatments after a follow-up of
up to 2 years.60 A meta-analysis focusing on risk of
iatrogenic reflux after POEM versus LHM suggested
the increased risk of GORD after POEM.61
Recommendation 2.6
Laparoscopic Heller myotomy combined with an anti-reflux pro-
cedure is an effective and relatively safe therapy for achalasia.
Strong recommendation, high certainty of evidence
Consensus: 100% agree [Vote: Aþþ, 100%; Aþ, 0%; A, 0%; D,
0%; Dþ, 0%; Dþþ, 0%]
2.7 What are predictors of treatment outcome?
How to choose initial treatment?
In order to guide therapeutic decisions, it is useful to
distinguish patient types that are likely to respond
favourably to a certain therapy. Patient-specific factors
such as age, sex, and manometric type are commonly
believed to be predictive of treatment outcome, with the
unfavourable effect of young age undoubtedly being the
most frequently described example.66–69 A recently pub-
lished review systematically assessed 75 studies that
investigated potential patient-specific predictors.70 A
total of 34 predictors were identified, but of all pre-ther-
apeutic factors, only age and manometric subtype were
identified as important predictors with a strong level of
cumulative evidence. A meta-analysis confirmed that
older patients (>45 years) responded better to PD
treatment than younger individuals. Manometric sub-
type 3 was associated with poor treatment outcome in
general. Interestingly, of the 49 included studies that
evaluated sex as potential predictor, 90% did not find
an association between sex and treatment outcome,
indicating that sex most likely is not of predictive
value in clinical decision making. The predictive value
of some of the studied factors, such as chest pain and
symptom severity remains unclear, as the total body of
evidence was inconclusive or insufficient to draw firm
conclusions. It is suggested that age and manometric
subtype should be taken into account when selecting a
therapeutic strategy, in conjunction with information
on efficacy and safety of the individual procedures,
patient preference, and local expertise.
Recommendation 2.7
We suggest taking age and manometric subtype into account when
selecting a therapeutic strategy.
Conditional recommendation, moderate certainty of evidence
Consensus: 100% agree [Vote: Aþþ, 100%; Aþ, 0%; A, 0%; D,
0%; Dþ, 0%; Dþþ, 0%]
2.8 Overall recommendations on treatment
(comparative effectiveness and safety)
Based on the systematic reviews and GRADE assess-
ments of research question 2.3 – 2.7 combined, the
working group proposes the following overall recom-
mendations with regard to achalasia therapy:
Recommendation 2.8
a. Treatment decisions in achalasia should be made based on
patient-specific characteristics, the patient’s preference, pos-
sible side effects and/or complications and a center’s expertise.
Overall, graded repetitive PD, LHM and POEM have comparable
efficacy.
Strong recommendation, moderate certainty of evidence
Consensus: 100% agree [Vote: Aþþ, 55.6%; Aþ, 44.4%; A, 0%; D
0%; Dþ, 0%; Dþþ, 0%]
b. Botulinum toxin therapy should be reserved for patients who
are too unfit for more invasive treatments, or in whom a more
definite treatment needs to be deferred.
Conditional recommendation, moderate certainty of evidence
Consensus: 100% agree [Vote: Aþþ, 100%; Aþ, 0%; A, 0%; D 0%;
Dþ, 0%; Dþþ, 0%]
2.9 How to treat post-Heller recurrence?
Minimally invasive surgical therapy in achalasia is
effective in the majority of patients, however symptom
relapse occurs in 10-20% of patients at the long term.55
No adequate prospective controlled trials have been
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conducted on management of failed Heller myotomy
due to low patient numbers. Current options for treat-
ment of Heller recurrence include endoscopic dilation,
POEM, or redo surgery. When no gross anatomic
abnormalities are present, PD or POEM can be con-
sidered. Both procedures show equally modest efficacy
rates, but PD is often regarded a less-invasive first
step.71–79 In the event of recurrence due to a too tight
or twisted fundoplication, or a more complex anatomy
with oesophageal distortion, fibrosis or a post-myot-
omy diverticulum, redo surgery may be considered.
However, this is associated with a substantial risk of
post-operative complications.74,80–82
Recommendation 2.9
We suggest treating recurrent or persistent dysphagia after lap-
aroscopic Heller myotomy with PD, POEM or redo surgery.
Conditional recommendation, very low certainty of evidence
Consensus: 100% agree [Vote: Aþþ, 22.2%; Aþ, 77.8%; A, 0%; D
0%; Dþ, 0%; Dþþ, 0%]
2.10 How to treat post-POEM recurrence
Although POEM has good-to-excellent efficacy rates,
treatment failure with recurrent or persistent symptoms
does occur.50,62,83 In a recently published randomised
controlled trial comparing endoscopic myotomy with
PD, the authors reported clinical failure in 8% of
patients treated with POEM after two years of follow-
up.50 Data on the best therapeutic approach after
POEM failure is limited. Two case series reported suc-
cess rates of 80-100% after three months of follow-up in
patients treated with re-POEM after initial failure.84,85
Another study evaluating retreatment after POEM fail-
ure in 43 patients, showed that retreatment with either
LHM or re-POEM gives modest efficacy rates of 45%
and 63%, respectively, whereas PD showed a poor effi-
cacy of only 20%.86 These results may indicate superior-
ity of both POEM and LHM compared to PD in the
management of POEM failure. However, it must be
noted, that the data to support this is weak and based
on case series only. Moreover, PD is feasible and avail-
able inmany centres, and is considered to be less invasive
than re-myotomy and can therefore not completely be
omitted in the management of this patient group.
Recommendation 2.10
We suggest treating recurrent or persistent dysphagia after POEM
with either re-POEM, laparoscopic Heller myotomy or pneumatic
dilation.
Conditional recommendation, very low certainty of evidence
Consensus: 100% agree [Vote: Aþþ, 77.8%; Aþ, 22.2%; A, 0%; D
0%; Dþ, 0%; Dþþ, 0%]
2.11 What are indications for oesophagectomy?
Oesophagectomy for achalasia is associated with a high
risk of complications and mortality.87,88 A systematic
review of 8 studies and 1307 patients that underwent
oesophagectomy, reported a complication rate of 19%-
50% and a mortality rate 0-3.8%.87 In a large series of
over 500 patients, oesophagectomy was initially per-
formed in less than 1% of the entire population, but
ultimately 17% of patients required oesophageal resec-
tion. Particularly those who failed surgical treatment or
those with end-stage achalasia, which is often asso-
ciated with massive oesophageal dilatation and tortu-
osity.82 In a report on 53 patients with end-stage
achalasia that underwent oesophageal resection, the
indications were tortuous mega-oesophagus (64%) or
oesophageal stricture formation due to reflux (7%).89
Other indications for oesophageal resection are pres-
ence of high-grade dysplasia or cancer. Although the
in-hospital mortality after esophagectomy is lower in
patients with achalasia than in patients with cancer
(2.8% vs. 7.7%, respectively), it is still a substantial
risk, especially as the indication for resection is not as
strong as for malignant disease. Moreover, the overall
post-operative complication rate is similar in both
patient groups.90 Hence, oesophagectomy should be
considered the last resort in end-stage achalasia,
where disabling symptoms reoccur despite aggressive
treatment.91,92 On the other hand, as the risk and com-
plexity of oesophageal resection increases with the
deterioration of a patient’s condition and nutritional
status, end-stage achalasia should be carefully fol-
lowed-up to promptly identify when oesophagectomy
is necessary.
Recommendation 2.11
Oesophagectomy should be considered the last resort to treat
achalasia, after all other treatments have been considered.
Expert opinion recommendation
Consensus: 100% agree [Vote: Aþþ, 77.8%; Aþ, 22.2%; A, 0%; D
0%; Dþ, 0%; Dþþ, 0%]
2.12 What is the role of alternative therapies in
the treatment of achalasia?
Several studies have investigated the use of alternative
therapies such as oesophageal stents93–101 and
intrasphincteric injection with ethanolamine oleate in
achalasia treatment.102–105 Overall, there is no high-
quality evidence to support that either of these thera-
pies are effective for symptom relief in achalasia
patients. Moreover, as occurrence of complications
such as bleeding, stent migration, or strictures are
fairly common, use of these therapies is not
recommended.
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Recommendation 2.12
We suggest against oesophageal stents and intrasphincteric injec-
tion of sclerosing agents in the treatment of achalasia.
Expert opinion recommendation
Consensus: 100% agree [Vote: Aþþ, 100%; Aþ, 0%; A, 0%; D 0%;
Dþ, 0%; Dþþ, 0%]
3. Achalasia follow-up
3.1 How to diagnose and manage recurrent or
persistent dysphagia after treatment?
Despite treatment, a proportion of patients will experi-
ence ongoing or recurrent symptoms that significantly
impair quality of life.86,106 In some cases, treatment
does not lead to meaningful improvement in the first
place (persistent symptoms). In others, a period of ini-
tial improvement is followed by subsequent recurrence.
In general terms, the former suggests that initial treat-
ment was incomplete, whereas the latter can be due to a
variety of causes. There is no universal definition of
what constitutes persistence or recurrence of symptoms.
In most trials an Eckardt score above 3 or a less than
50% improvement in symptoms is regarded as treat-
ment failure.47,50,54,107–109 However, this fails to distin-
guish between dysphagia, and alternative troublesome
symptoms such as regurgitation or chest pain.
Although dysphagia is the most common ongoing
symptom after achalasia treatment,86 the aetiology
may be different to that in the treatment-naive setting
(Table 3.1.1).
Given the wide variety of potential causes of recur-
rent dysphagia, it is critical to undertake a comprehen-
sive evaluation using objective testing in order to
determine the pathophysiology underpinning the recur-
rent symptoms, and thus select appropriate treatment.
Conversely, in selected cases of persistent dysphagia,
where the diagnosis of achalasia is beyond doubt, it
may be appropriate to proceed immediately to further
treatment without repeat testing (for example, POEM
after failure to improve with PD).
Since the commonest causes of recurrent dysphagia
are incomplete myotomy, post-treatment scarring, and
oesophageal stasis due to aperistalsis and functional
dysphagia, objective testing should be targeted at
these conditions. Timed barium esophagram helps
determine if there is persistent delay to oesophageal
emptying, but reports regarding its usefulness as a pre-
dictor of long-term treatment success are conflict-
ing.36,55,108 High-resolution manometry provides
additional information on LOS pressure. Impedance
planimetry might be a useful complementary tool to
assess OGJ distensibility and determine treatment effi-
cacy.16,110 In patients with a suspicion of severe
oesophagitis, possible candida oesophagitis or ana-
tomic abnormalities endoscopy should be considered.
Recommendation 3.1
a. Patients with recurrent or persistent dysphagia after initial
treatment should undergo repeat evaluation with timed
barium esophagram with or without oesophageal manometry.
Expert opinion recommendation
Consensus: 100% agree [Vote: Aþþ, 100%; Aþ, 0%; A, 0%; D 0%;
Dþ, 0%; Dþþ, 0%]
b. Repeat endoscopy should be considered in patients with recur-
rent dysphagia.
Expert opinion recommendation
Consensus: 100% agree [Vote: Aþþ, 66.7%; Aþ, 33.3%; A, 0%; D
0%; Dþ, 0%; Dþþ, 0%]
3.2 How to diagnose and manage recurrent or
persistent chest pain after treatment?
Although chest pain is one of the main presenting symp-
toms of achalasia, its response to treatment is less well
studied and remarkably underreported, most likely as
dysphagia is considered the leading and most relevant
symptom. Nevertheless, up to 64% of patients report
chest pain, often occurring in the middle of the night
(in 47% of patients with chest pain) and lasting from a
few minutes to almost 24 hours.111 In contrast to dys-
phagia, chest pain is more challenging to treat and rep-
resents a risk factor for unsatisfactory treatment results
for both pneumatic dilation (PD) and laparoscopic
Heller myotomy (LHM).37,54,112 In approximately 19%
of patients, chest pain is completely relieved following
LHM, but in the remainder chest pain persists, with an
intensity that is less (73%), similar (21%) or even more
severe (4%) than before surgery.113 Comparable results
have been reported for PD.111 Of note, chest pain per-
sists in these patients even though dysphagia was
Table 3.1.1. Potential causes for persistent and recurrent dys-
phagia after initial treatment.
Common
 Persistent OGJ non-relaxation (e.g. incomplete myotomy)
 Post-treatment oesophageal fibrosis/scarring
 Excessively tight fundoplication post-myotomy
 Gastro-oesophageal reflux (with or without oesophagitis)
 Aperistalsis and oesophageal stasis
 Functional dysphagia
Uncommon
 Development of malignant stricture
 Wrap migration after fundoplication and myotomy
 Benign stricture (e.g. from reflux)
 Extrinsic compression from hiatal hernia (para-oesophageal)
or post-treatment collection
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successfully treated. In general, achalasia-associated
chest pain seems to decrease with time, but complete
disappearance is rather exceptional.111
The exact cause underlying (non-cardiac) chest pain
remains unknown, and can be attributed to acid reflux,
oesophageal motor abnormalities or visceral hypersen-
sitivity. However, as chest pain is also considered to
result from oesophageal distension as a result of incom-
plete emptying, treatment failure should first be
excluded in patients with persistent or recurrent chest
pain by performing oesophageal manometry and timed
barium esophagram (TBE).
If manometry (IRP above cut-off; catheter-depend-
ing, varying between 15 and 28 mmHg)114 or TBE are
abnormal (barium column height of >5cm after 5 min-
utes),115 treatment should aim to normalize oesopha-
geal emptying. HRM also serves to exclude spastic
contractions as cause of the pain. If there is no evidence
indicating insufficient treatment, one can consider
investigation for gastro-oesophageal reflux (GER) as
trigger of chest pain using 24-hour pH (impedance)
monitoring and treat accordingly.116 Data demonstrat-
ing the effect of PPI on chest pain in achalasia are how-
ever lacking, and anecdotally the response to PPI is
poor if there is chest pain without heartburn.
Themanagement of achalasia patients with chest pain
with no evidence of GER and normal oesophageal emp-
tying/IRP remains amajor challenge, mainly as there are
no or only a limited number of randomised clinical trials
available. Hence, clinical decision making is mostly
based on studies performed in patients with non-cardiac
chest pain due to oesophageal dysmotility. Potential
options for medical treatment are smooth muscle relax-
ants (nifedipine, nitrates, diltiazem), botulinum toxin
injection or neuromodulators (imipramine, venlafaxine,
sertraline)116; however, the success rates are rather lim-
ited and/or the effect is short lasting (in case of botulinum
toxin). Of interest, evidence is accumulating that POEM
might be effective in relieving chest pain, both in patients
with achalasia and other primary oesophageal motility
disorders. Several case series evaluating patients with
hypercontractile oesophageal motility disorders and
chest pain that were treated with POEM showed promis-
ing results.117–120 However, as none of the studies were
sham-controlled, patient numbers were small and
lengths of follow-up relatively short, future controlled
data with longer follow-up is needed to investigate the
exact role of POEM for patients with chest pain after
initial achalasia treatment.
Recommendation 3.2
a. In patients with persistent or recurrent chest pain, inappropriate
emptying due to ineffective initial treatment or recurrent disease
should be excluded by TBE with or without oesophageal
(continued)
Continued.
manometry. For type III achalasia, we suggest a repeat HRM to
exclude or confirm persistent spastic contractions.
Expert opinion recommendation
Consensus: 100% agree [Vote: Aþþ, 88.9%; Aþ, 11.1%; A, 0%; D
0%; Dþ, 0%; Dþþ, 0%]
b. If there is no evidence of impaired oesophageal emptying,
empirical treatment with PPI, endoscopy and/or 24-hour pH
(impedance) monitoring can be considered.
Expert opinion recommendation
Consensus: 100% agree [Vote: Aþþ, 100%; Aþ, 0%; A, 0%; D 0%;
Dþ, 0%; Dþþ, 0%]
3.3 How to manage reflux disease after
treatment?
As the aim of achalasia treatment is to alleviate the
OGJ obstruction, an expected side effect of treatment
is the occurrence of gastro-oesophageal reflux disease
(GORD), usually defined in achalasia as the presence of
reflux oesophagitis or pathological acid exposure.
Indeed GORD is frequently observed after treatment
(10 to 31% of cases after pneumatic dila-
tion51–53,55,58,121 5 to 35% after Heller’s myot-
omy52,53,55,121–123 and up to 60% of patients after
POEM)50,60,61,124–126 GORD complications including
peptic stricture, Barrett’s mucosa, and oesophageal
adenocarcinoma have been reported after achalasia
treatment.124,126–130 Comparative studies demonstrated
that the rate of GORD was similar after PD and LHM
with fundoplication.121 One study showed that LHM
without lateral and posterior dissection might also
achieve sufficient reflux control.131 However, in other
studies, prevalence of GORD was significantly higher
after POEM or laparoscopic Heller myotomy without
fundoplication than after pneumatic dilation or laparo-
scopic Heller myotomy with fundoplication.50,60,62,132
Therefore, systematic screening for GORD after acha-
lasia treatment should be recommended if the risk for
GORD is high. Moreover, due to the different GORD
rates, the choice of achalasia treatment should take into
account the risk of iatrogenic reflux disease. In line with
this, empiric PPI therapy might be considered in
patients that underwent myotomy without an anti-
reflux procedure.
GORD symptoms such as heartburn and regurgita-
tion are not reliable to diagnose GORD in achala-
sia patients, especially as regurgitation is also a
hallmark of achalasia and poor oesophageal emptying.
Upper endoscopy can reveal oesophagitis and
Barrett’s mucosa as proof of GORD. Another way
to diagnose GORD is 24-h oesophageal pH monitor-
ing. The interpretation of this examination requires a
careful review of pH tracings to eliminate periods of
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oesophageal fermentation.53 The correlation between
oesophageal symptoms and objective diagnosis of
GORD (including oesophagitis and oesophageal acid
exposure) is poor.62,123,133–135 Upper GI endoscopy,
TBE and 24-h pH monitoring might be
complementary.
So far, no study has clearly evaluated the man-
agement of GORD after achalasia treatment. Post-
treatment GORD is usually treated successfully with
PPI. The percentage of patients on PPI after acha-
lasia treatment is up to 60%.60,61,136–138 Few other
GORD treatments have been proposed for refractory
cases and presented only as case reports




a. We suggest follow-up endoscopy to screen for GORD in patients
treated with myotomy without anti-reflux procedure.
Expert opinion recommendation
Consensus: 100% agree [Vote: Aþþ, 44.4%; Aþ, 44.4%; A, 11.1%;
D 0%; Dþ, 0%; Dþþ, 0%]
b. In case of reflux symptoms in absence of reflux oesophagitis,
TBE, empiric PPI therapy, and/or 24-h oesophageal pH-(imped-
ance)monitoring can be considered.
Expert opinion recommendation
Consensus: 100% agree [Vote: Aþþ, 77.8%; Aþ, 22.2%; A, 0%; D
0%; Dþ, 0%; Dþþ, 0%]
c. Proton pump inhibitors are the first line treatment of GORD
after achalasia treatment. We recommend lifelong PPI
therapy in patients with oesophagitis> grade A (LA
classification).
Expert opinion recommendation
Consensus: 100% agree [Vote: Aþþ, 33.3%; Aþ, 55.6%; A, 11.1%;
D 0%; Dþ, 0%; Dþþ, 0%]
3.4 Is surveillance endoscopy for dysplasia
needed?
What is the incidence of oesophageal cancer in achalasia
patients?
Achalasia is a risk factor for oesophageal cancer. Poor
oesophageal clearance increases bacterial growth, chem-
ical irritation and mucosal inflammation that can facili-
tate dysplastic changes of oesophageal epithelial cells
and result in squamous cell carcinoma (SCC).141
Furthermore, acid exposure secondary to reduction of
oesophago-gastric junction pressure as a consequence
of achalasia treatment may lead to Barrett’s mucosa
and oesophageal adenocarcinoma (EA).142
The exact level of risk for oesophageal cancer (SCC
and EA) is controversial. Differences in study design
(retrospective or prospective, length of Follow-up,
number of patients, countries) might explain some of
the observed differences. While the absolute risk of
oesophageal cancer is quite low in achalasia, the rela-
tive risk of cancer is higher in achalasia patients than in
the general population (risk ratio to develop EA and
SCC in achalasia patients is 6.63 and 72.65 respect-
ively).143,144 Most of the cases of carcinoma are
observed more than 10 years after symptom
onset.144,145 The type of treatment does not influence
the risk of cancer130,146 but to date there are no long-
term data following POEM. Cancer risk might be
higher in males and in patients with Chagas
disease.130,146,147
Screening practices differ among geographic regions
(routine endoscopy versus no endoscopy, screening
intervals).92,148 Chromoendoscopy with lugol was pro-
posed to improve the detection rate of dysplastic lesion
but the yield was low and hampered by stratification
risk.145
Finally the cost efficacy of the screening has not been
demonstrated; the low absolute risk of cancer and the
difficulty to identify pre-neoplastic lesions might
explain the absence of advantage to screen achalasia
patients for oesophageal cancer.
Recommendation 3.4
We suggest against performing systematic screening for dysplasia
and carcinoma. However, the threshold of upper GI endoscopy
should be low in patients with recurrent symptoms and longstand-
ing achalasia.
Conditional recommendation, low certainty of evidence
Consensus: 100% agree [Vote: Aþþ, 66.7%; Aþ, 33.3%; A, 0%; D
0%; Dþ, 0%; Dþþ, 0%]
Conclusions and future perspectives
The ESNM/UEG guidelines on the management of
achalasia are the result of an evidence-based approach
and international and multidisciplinary efforts. These
guidelines provide recommendations for key aspects
of the diagnosis and management of achalasia, com-
bined with comments based on the best-available litera-
ture and the opinions of leading European achalasia
experts. The main objective of these guidelines is to
reduce variation in practice and improve patient out-
comes across Europe. Consequently, thorough and
extensive dissemination of these guidelines is needed
to assure high compliance in clinical practice.
Promotion of the guideline as well as education play
a key role in this regard. Future well-designed clinical
trials should address the gaps of knowledge and unmet
needs that have arisen during the development of this
guideline.
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